pembrolizumab
Cofactor Quickly Moving Immunotherapy Predictive Test to Market With Data From Intermountain Spinout
Premium
Culmination Bio's 4.5 million biospecimens and longitudinal omics and clinical data may help Cofactor rapidly advance the OncoPrism assay into multiple cancer types.
Culmination Bio, Cofactor Genomics Team up on Study to Advance Immunotherapy Response Test
Culmination will give Cofactor access to over 4.5 million biological samples to advance the firm's assay to predict immunotherapy response in 11 cancer types.
Biomarker Predicts Immunotherapy Benefit in Head and Neck Cancer but Commercial Path Unclear
Premium
Somatic 9p24.1 copy number alterations predicted the degree to which HPV-negative advanced squamous head and neck cancers benefitted from Keytruda and Opdivo.
Personalis, Duke University, Olink Collaborate on Immunotherapy Markers in Gastric Cancer
They plan to study the genomic, transcriptomic, and proteomic responses of gastroesophageal tumors following treatment with Merck's Keytruda.
NCCN Publishes First Guidelines for Pediatric Brain Cancer, Recommends Broad NGS Profiling
The guidelines recognize the importance of molecular profiling in diagnosing, treating, and identifying clinical trial opportunities for children with high-grade gliomas.